|1.||Kitazawa, Masashi: 1 article (02/2014)|
|2.||Cheng, David: 1 article (02/2014)|
|3.||Castello, Nicholas A: 1 article (02/2014)|
|4.||Green, Kim N: 1 article (02/2014)|
|5.||LaFerla, Frank M: 1 article (02/2014)|
|6.||Decker, Michael W: 1 article (02/2014)|
|7.||Esbenshade, Timothy A: 1 article (02/2014)|
|8.||Bitner, Robert S: 1 article (02/2014)|
|9.||Medeiros, Rodrigo: 1 article (02/2014)|
|10.||Baglietto-Vargas, David: 1 article (02/2014)|
02/01/2014 - "In the present study, we determined the effect of long-term treatment with the selective α7 nAChR agonist A-582941 in aged 3xTg-AD mice with robust AD-like pathology, which is particularly significant not only because this is the only mouse model that co-develops amyloid plaques and neurofibrillary tangles but also because it enabled us to explore whether A-582941 is able to restore brain function after the severe damage associated with AD. "
|2.||AIDS-Related Complex (ARC)
06/23/2008 - "Furthermore, A-582941 increased the number of Arc and c-Fos immunopositive cells in the mPFC, VO/LO, and shell of the nucleus accumbens, in both juvenile and adult rats. "
06/23/2008 - "Acute administration of A-582941 (1, 3, 10 mg/kg) induced a dose-dependent increase in Arc mRNA expression in the medial prefrontal cortex (mPFC) and the ventral/lateral orbitofrontal (VO/LO) cortex of juvenile, but not adult rats. "
|2.||Messenger RNA (mRNA)